Toll Free: 1-888-928-9744

Virobay Inc. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Virobay Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Virobay Inc. - Product Pipeline Review - 2014', provides an overview of the Virobay Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Virobay Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Virobay Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Virobay Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Virobay Inc.'s pipeline products

Reasons to buy

- Evaluate Virobay Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Virobay Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Virobay Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Virobay Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Virobay Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Virobay Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Virobay Inc. Snapshot 5
Virobay Inc. Overview 5
Key Information 5
Key Facts 5
Virobay Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Virobay Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Virobay Inc. - Pipeline Products Glance 13
Virobay Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Phase 0 Products/Combination Treatment Modalities 14
Virobay Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Virobay Inc. - Drug Profiles 17
VBY-036 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
VBY-129 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
VBY-376 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
VBY-285 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
VBY-825 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
VBY-X 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Inhibit Cathepsin Protease for Alzheimer's disease 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Inhibit Cathepsin Protease for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Virobay Inc. - Pipeline Analysis 25
Virobay Inc. - Pipeline Products by Target 25
Virobay Inc. - Pipeline Products by Route of Administration 26
Virobay Inc. - Pipeline Products by Molecule Type 27
Virobay Inc. - Pipeline Products by Mechanism of Action 28
Virobay Inc. - Recent Pipeline Updates 29
Virobay Inc. - Dormant Projects 30
Virobay Inc. - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Virobay Inc., Key Information 5
Virobay Inc., Key Facts 5
Virobay Inc. - Pipeline by Indication, 2014 8
Virobay Inc. - Pipeline by Stage of Development, 2014 9
Virobay Inc. - Monotherapy Products in Pipeline, 2014 10
Virobay Inc. - Out-Licensed Products in Pipeline, 2014 11
Virobay Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Virobay Inc. - Phase I, 2014 13
Virobay Inc. - Phase 0, 2014 14
Virobay Inc. - Preclinical, 2014 15
Virobay Inc. - Discovery, 2014 16
Virobay Inc. - Pipeline by Target, 2014 25
Virobay Inc. - Pipeline by Route of Administration, 2014 26
Virobay Inc. - Pipeline by Molecule Type, 2014 27
Virobay Inc. - Pipeline Products by Mechanism of Action, 2014 28
Virobay Inc. - Recent Pipeline Updates, 2014 29
Virobay Inc. - Dormant Developmental Projects,2014 30
Virobay Inc., Other Locations 31 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify